Needham Maintains Buy on Phathom Pharmaceuticals, Lowers Price Target to $22

Benzinga Newsdesk www.benzinga.com Neutral 47.6%

Neg 0% Neu 47.6% Pos 0%

Needham analyst Joseph Stringer maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and lowers the price target from $28 to $22.